$OPK
OPKO HEALTH, INC. Stock $opk

$opk Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000094480920000018 Filed on May 06, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$211.5M	$222.5M
YoY Change	-4.94%	-12.73%
Cost Of Revenue	$140.3M	$144.1M
YoY Change	-2.64%	3.34%
Gross Profit	$71.20M	$78.40M
YoY Change	-9.18%	-32.11%
Gross Profit Margin	33.67%	35.24%
Selling, General & Admin	$76.13M	$95.16M
YoY Change	-19.99%	3.98%
% of Gross Profit	106.93%	121.38%
Research & Development	$21.76M	$36.53M
YoY Change	-40.43%	11.07%
% of Gross Profit	30.56%	46.59%
Depreciation & Amortization	$22.05M	$23.82M
YoY Change	-7.41%	-3.8%
% of Gross Profit	30.97%	30.38%
Operating Expenses	$252.2M	$297.8M
YoY Change	-15.29%	0.08%
Operating Profit	-$40.76M	-$75.32M
YoY Change	-45.88%	76.76%
Interest Expense	-$4.700M	-$3.800M
YoY Change	23.68%	375.0%
% of Operating Profit
Other Income/Expense, Net	-$17.07M	-$2.807M
YoY Change	507.94%	-364.56%
Pretax Income	-$57.83M	-$78.13M
YoY Change	-25.98%	88.03%
Income Tax	$1.171M	$783.0K
% Of Pretax Income
Net Earnings	-$59.13M	-$80.76M
YoY Change	-26.78%	87.32%
Net Earnings / Revenue	-27.96%	-36.31%
Basic Earnings Per Share	-$0.09
Diluted Earnings Per Share	-$0.09	-$137.8K
COMMON SHARES
Basic Shares Outstanding	669.8M shares	615.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$34.50M	$207.3M
YoY Change	-83.36%	107.51%
Cash & Equivalents	$34.53M	$207.3M
Short-Term Investments
Other Short-Term Assets	$15.79M	$4.511M
YoY Change	249.94%	3.23%
Inventory	$58.70M	$44.61M
Prepaid Expenses
Receivables	$132.5M	$144.4M
Other Receivables	$14.20M	$19.40M
Total Short-Term Assets	$274.5M	$435.2M
YoY Change	-36.94%	24.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$127.3M	$140.0M
YoY Change	-9.05%	-5.89%
Goodwill	$710.0M	$712.0M
YoY Change	-0.28%	-1.1%
Intangibles
YoY Change
Long-Term Investments	$10.60M	$31.40M
YoY Change	-66.24%	-13.5%
Other Assets	$7.026M	$3.126M
YoY Change	124.76%	-44.45%
Total Long-Term Assets	$1.958B	$2.140B
YoY Change	-8.5%	-4.01%
TOTAL ASSETS
Total Short-Term Assets	$274.5M	$435.2M
Total Long-Term Assets	$1.958B	$2.140B
Total Assets	$2.233B	$2.575B
YoY Change	-13.31%	-0.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$55.87M	$51.09M
YoY Change	9.36%	-20.46%
Accrued Expenses	$164.9M	$217.5M
YoY Change	-24.18%	0.18%
Deferred Revenue	$10.46M	$65.29M
YoY Change	-83.99%	6.37%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$15.40M	$115.4M
YoY Change	-86.66%	187.78%
Total Short-Term Liabilities	$245.1M	$396.1M
YoY Change	-38.12%	24.52%
LONG-TERM LIABILITIES
Long-Term Debt	$3.538M	$4.322M
YoY Change	-18.14%	201.82%
Other Long-Term Liabilities	$77.76M	$78.17M
YoY Change	-0.52%	-66.54%
Total Long-Term Liabilities	$438.8M	$416.5M
YoY Change	5.36%	-4.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$245.1M	$396.1M
Total Long-Term Liabilities	$438.8M	$416.5M
Total Liabilities	$683.9M	$812.6M
YoY Change	-15.83%	7.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.572B	-$1.277B
YoY Change	23.07%	18.76%
Common Stock	$6.704M	$6.162M
YoY Change	8.8%	10.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.791M	$1.791M
YoY Change	0.0%	0.0%
Treasury Stock Shares	549.9K shares	549.9K shares
Shareholders Equity	$1.549B	$1.763B
YoY Change
Total Liabilities & Shareholders Equity	$2.233B	$2.575B
YoY Change	-13.31%	-0.14%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$59.13M	-$80.76M
YoY Change	-26.78%	87.32%
Depreciation, Depletion And Amortization	$22.05M	$23.82M
YoY Change	-7.41%	-3.8%
Cash From Operating Activities	-$43.37M	-$48.99M
YoY Change	-11.47%	37.92%
INVESTING ACTIVITIES
Capital Expenditures	-$5.600M	-$2.900M
YoY Change	93.1%	-51.67%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$1.200M
YoY Change	-100.0%	-250.0%
Cash From Investing Activities	-$5.619M	-$4.132M
YoY Change	35.99%	-19.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.611M	$163.9M
YoY Change	-100.98%	233.14%
NET CHANGE
Cash From Operating Activities	-$43.37M	-$48.99M
Cash From Investing Activities	-$5.619M	-$4.132M
Cash From Financing Activities	-$1.611M	$163.9M
Net Change In Cash	-$50.92M	$110.8M
YoY Change	-145.97%	1211.9%
FREE CASH FLOW
Cash From Operating Activities	-$43.37M	-$48.99M
Capital Expenditures	-$5.600M	-$2.900M
Free Cash Flow	-$37.77M	-$46.09M
YoY Change	-18.05%	56.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000944809
CY2019Q4	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	11	institution
CY2018Q3	opk	Number Of Derivative Lawsuits NumberOfDerivativeLawsuits	12	lawsuit
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	670378701	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	670378701	shares
CY2019Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1100000000	USD
CY2018	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.01
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	549907	shares
CY2020Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	549907	shares
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-33528
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	OPKO Health, Inc.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-2402409
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4400 Biscayne Blvd.
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33137
CY2020Q1	dei	City Area Code CityAreaCode	(305)
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	575-4100
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2020Q1	dei	Trading Symbol TradingSymbol	OPK
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	669828524	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34530000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85452000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	132476000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	134617000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	58697000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	53434000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	48754000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50542000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	274457000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	324045000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127304000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127111000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	513511000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	528962000	USD
CY2020Q1	opk	In Process Researchand Development InProcessResearchandDevelopment	590200000	USD
CY2019Q4	opk	In Process Researchand Development InProcessResearchandDevelopment	590200000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	669582000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	671940000	USD
CY2020Q1	us-gaap	Long Term Investments LongTermInvestments	10669000	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	20746000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39793000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39380000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7026000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6888000	USD
CY2020Q1	us-gaap	Assets Assets	2232542000	USD
CY2019Q4	us-gaap	Assets Assets	2309272000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	55866000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	62537000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	164939000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	164925000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11480000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12038000	USD
CY2020Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	12802000	USD
CY2019Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	9619000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	245087000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	249119000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28669000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27665000	USD
CY2020Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	213805000	USD
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	211208000	USD
CY2020Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	118600000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	118717000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	77762000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	87804000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17065000	USD
CY2020Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	438836000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	445394000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	683923000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	694513000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	6704000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	6704000	USD
CY2020Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1791000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1791000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3145444000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3142993000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-30187000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-22070000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1571551000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1511077000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1548619000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1614759000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2232542000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2309272000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	211466000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	222451000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	76132000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	95158000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21760000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36529000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-860000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4806000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14938000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16562000	USD
CY2020Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	655000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	252228000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	297769000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-40762000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-75318000	USD
CY2020Q1	opk	Interest Income Nonoperating InterestIncomeNonoperating	142000	USD
CY2019Q1	opk	Interest Income Nonoperating InterestIncomeNonoperating	556000	USD
CY2020Q1	opk	Interest Expense Nonoperating InterestExpenseNonoperating	5496000	USD
CY2019Q1	opk	Interest Expense Nonoperating InterestExpenseNonoperating	4755000	USD
CY2020Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	621000	USD
CY2019Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	415000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12332000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	977000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-57827000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2807000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-78125000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1171000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	783000	USD
CY2020Q1	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	-58998000	USD
CY2019Q1	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	-78908000	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-134000	USD
CY2019Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1854000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-59132000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-80762000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	640578794	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	586344207	shares
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-59132000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-80762000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8117000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3098000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-67249000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-83860000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1614759000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2451000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2020Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-1342000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	0	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-59132000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8117000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1548619000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1791291000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4457000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-3000	USD
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	50852000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-80762000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3098000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1762737000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-59132000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-80762000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22052000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23816000	USD
CY2020Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	2483000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	203000	USD
CY2019Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	3010000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	405000	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-134000	USD
CY2019Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1854000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2451000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4457000	USD
CY2020Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-102000	USD
CY2019Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-284000	USD
CY2020Q1	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	-9259000	USD
CY2019Q1	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	1825000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-860000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4806000	USD
CY2020Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	655000	USD
CY2020Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	613000	USD
CY2019Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-352000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	763000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	439000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8831000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2475000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	729000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	46000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-60000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	243000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4865000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3713000	USD
CY2020Q1	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	56000	USD
CY2019Q1	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	-23000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-9451000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-18073000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3848000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	12250000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43370000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48988000	USD
CY2020Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2019Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1200000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7000	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2020Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5626000	USD
CY2019Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2932000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5619000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4132000	USD
CY2020Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2019Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	200293000	USD
CY2020Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	7762000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	-3000	USD
CY2020Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	186398000	USD
CY2019Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	35460000	USD
CY2020Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	188009000	USD
CY2019Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	35313000	USD
CY2020Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
CY2019Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	28800000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1611000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	163875000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-322000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50922000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	110777000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85452000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96473000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34530000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	207250000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	5012000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	511000	USD
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	799000	USD
CY2019Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1022000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	33277000	USD
CY2020Q1	opk	Operating Lease Liability Initial Recognition Upon Adoption OperatingLeaseLiabilityInitialRecognitionUponAdoption	0	USD
CY2019Q1	opk	Operating Lease Liability Initial Recognition Upon Adoption OperatingLeaseLiabilityInitialRecognitionUponAdoption	33744000	USD
CY2020Q1	opk	Common Stock Warrants Net Exercised CommonStockWarrantsNetExercised	0	USD
CY2019Q1	opk	Common Stock Warrants Net Exercised CommonStockWarrantsNetExercised	20000	USD
CY2020Q1	opk	Numberof Sales Employees NumberofSalesEmployees	300	employee
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Use of estimates</span><span style="font-family:inherit;font-size:10pt;">. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.</span></div>
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	600000	USD
CY2019Q1	us-gaap	Inventory Write Down InventoryWriteDown	500000	USD
CY2020Q1	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1800000000	USD
CY2020Q1	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1800000000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	669600000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	671900000	USD
CY2020Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1100000000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14900000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16600000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	7100000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	7300000	USD
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of credit risk and allowance for credit losses</span><span style="font-family:inherit;font-size:10pt;">. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the health care industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span></div>While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk since the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1700000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1900000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	USD
CY2019Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	200000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2500000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4500000	USD
CY2019Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	19232	shares
CY2019Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	24877	shares
CY2020Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	0	shares
CY2020Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	0	shares
CY2019Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	24877	shares
CY2019Q1	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	5645	shares
CY2020Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	134223000	USD
CY2019Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	136551000	USD
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1747000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1934000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	132476000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	134617000	USD
CY2020Q1	us-gaap	Other Inventory Supplies OtherInventorySupplies	28010000	USD
CY2019Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	23005000	USD
CY2020Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	23729000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	25142000	USD
CY2020Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	4260000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3238000	USD
CY2020Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	4591000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4586000	USD
CY2020Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1893000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2537000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	58697000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	53434000	USD
CY2020Q1	opk	Taxes Recoverable Current TaxesRecoverableCurrent	13577000	USD
CY2019Q4	opk	Taxes Recoverable Current TaxesRecoverableCurrent	19808000	USD
CY2020Q1	us-gaap	Supplies Supplies	12602000	USD
CY2019Q4	us-gaap	Supplies Supplies	8147000	USD
CY2020Q1	us-gaap	Prepaid Insurance PrepaidInsurance	6143000	USD
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3486000	USD
CY2020Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	646000	USD
CY2019Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3262000	USD
CY2020Q1	us-gaap	Other Assets Current OtherAssetsCurrent	15786000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	15839000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	48754000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50542000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	311710000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	298234000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	513511000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	528962000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10455000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	19196000	USD
CY2020Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	35325000	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	33671000	USD
CY2020Q1	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	37647000	USD
CY2019Q4	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	38635000	USD
CY2020Q1	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	7540000	USD
CY2019Q4	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	8122000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2375000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2375000	USD
CY2020Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2598000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2743000	USD
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	903000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1333000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	68096000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	58850000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	164939000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	164925000	USD
CY2020Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	39311000	USD
CY2019Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	44749000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	6448000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7308000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3538000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3906000	USD
CY2020Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3489000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4046000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1861000	USD
CY2020Q1	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	23115000	USD
CY2019Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	25224000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	77762000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	87804000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	671940000	USD
CY2020Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-2358000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	669582000	USD
CY2020Q1	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	711000	USD
CY2020Q1	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	1427000	USD
CY2020Q1	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	875000	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	8990000	USD
CY2020Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	35000	USD
CY2020Q1	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	58000	USD
CY2020Q1	us-gaap	Long Term Investments LongTermInvestments	10669000	USD
CY2020Q1	us-gaap	Equity Method Investment Summarized Financial Information Assets EquityMethodInvestmentSummarizedFinancialInformationAssets	68200000	USD
CY2020Q1	us-gaap	Equity Method Investment Summarized Financial Information Liabilities EquityMethodInvestmentSummarizedFinancialInformationLiabilities	38000000.0	USD
CY2020Q1	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	-21900000	USD
CY2020Q1	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	5400000	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-9880000	USD
CY2020Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-9880000	USD
CY2020Q1	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	11	institution
CY2020Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	98656000	USD
CY2020Q1	us-gaap	Line Of Credit LineOfCredit	50187000	USD
CY2019Q4	us-gaap	Line Of Credit LineOfCredit	52077000	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	8990000	USD
CY2020Q1	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	58000	USD
CY2020Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	9529000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	8823000	USD
CY2020Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	8823000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	18870000	USD
CY2019Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	120000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	19123000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9683000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	9683000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	8800000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9700000	USD
CY2018Q4	opk	Private Placement Agreement Sale Of Shares Shares PrivatePlacementAgreementSaleOfSharesShares	26500000	shares
CY2018Q4	opk	Private Placement Agreement Sale Of Shares Price Per Share PrivatePlacementAgreementSaleOfSharesPricePerShare	3.49
CY2018Q4	opk	Private Placement Agreement Sale Of Shares Amount PrivatePlacementAgreementSaleOfSharesAmount	92500000	USD
CY2019Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	37000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	8800000	USD
CY2020Q1	opk	Number Of Class Action Lawsuits NumberOfClassActionLawsuits	2	lawsuit
CY2018Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	100000	USD
CY2020Q1	us-gaap	Purchase Obligation PurchaseObligation	101100000	USD
CY2020Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	8900000	USD
CY2019Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	8400000	USD
CY2020Q1	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	23500000	USD
CY2019Q4	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	27300000	USD
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12300000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	21800000	USD
CY2017Q4	opk	Proceeds From Development And License Agreement Upfront Payment ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment	6000000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	USD
CY2020Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-40762000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-75318000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22052000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23816000	USD
CY2020Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-134000	USD
CY2019Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1854000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	211466000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	222451000	USD
CY2020Q1	us-gaap	Assets Assets	2232542000	USD
CY2019Q4	us-gaap	Assets Assets	2309272000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	669582000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	671940000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39793000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39380000	USD
CY2020Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	6087000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	6789000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11480000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12038000	USD
CY2020Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2598000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2743000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28669000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27665000	USD
CY2020Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3489000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4046000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2020Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063
CY2020Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.036
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.030
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	9601000	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	2122000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7079000	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2186000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6108000	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	1171000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5457000	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	586000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4297000	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	242000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	17189000	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	49731000	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	6307000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9582000	USD
CY2020Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	220000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	40149000	USD
CY2020Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	6087000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4600000	USD
CY2020Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	700000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	800000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	5700000	USD
CY2019Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1700000	USD
CY2019Q1	us-gaap	Variable Lease Cost VariableLeaseCost	1700000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4698000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	5742000	USD
CY2020Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	45000	USD
CY2019Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	191000	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	493000	USD
CY2019Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	660000	USD
CY2020Q1	opk	Payments For Leases PaymentsForLeases	5236000	USD
CY2019Q1	opk	Payments For Leases PaymentsForLeases	6593000	USD

Files In Submission

Name	View Source	Status
0000944809-20-000018-index-headers.html	Edgar Link	pending
0000944809-20-000018-index.html	Edgar Link	pending
0000944809-20-000018.txt	Edgar Link	pending
0000944809-20-000018-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opk-20200331.xsd	Edgar Link	pending
opk-20200331_cal.xml	Edgar Link	unprocessable
opk-20200331_def.xml	Edgar Link	unprocessable
opk-20200331_lab.xml	Edgar Link	unprocessable
opk-20200331_pre.xml	Edgar Link	unprocessable
opk-3312020x10q.htm	Edgar Link	pending
opk-3312020x10q_htm.xml	Edgar Link	completed
opk-3312020xex311.htm	Edgar Link	pending
opk-3312020xex312.htm	Edgar Link	pending
opk-3312020xex321.htm	Edgar Link	pending
opk-3312020xex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPK
OPKO HEALTH, INC. Stock $opk

2020 Q1 Form 10-Q Financial Statement

#000094480920000018 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK OPKO HEALTH, INC. Stock $opk

2020 Q1 Form 10-Q Financial Statement

#000094480920000018 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK
OPKO HEALTH, INC. Stock $opk